Craif
Craif is a venture company founded in 2018 originating from Nagoya University, specializing in high-precision detection of disease-related bio-substances such as microRNA from easily collectible body fluids like urine. The company is committed to early detection of cancer and personalized medicine using its proprietary platform, NanoIP™. Craif aims to develop innovative diagnostic tests to improve early cancer detection and tailored healthcare.
Industries
Nr. of Employees
small (1-50)
Craif
Patents
Method for patterning a substrate, a method for forming a microstructure on a substrate, and a method for fabricating a fluidic device
US-12338523-B2
View DetailsDevice to be used for capturing extracellular vesicles, and preservation method and transport method for extracellular vesicles
US-12038360-B2
View Details
Method for patterning a substrate, a method for forming a microstructure on a substrate, and a method for fabricating a fluidic device
US-12338523-B2
View DetailsDevice to be used for capturing extracellular vesicles, and preservation method and transport method for extracellular vesicles
US-12038360-B2
View DetailsProducts
Urine-based non-invasive cancer risk test (home and clinical kit)
A diagnostic offering that uses urine sampling, NGS-based microRNA profiling, and machine learning models to estimate risk for multiple cancer types. Available both as a home (remote) collection kit and via partner medical institutions.
Urine-based non-invasive cancer risk test (home and clinical kit)
A diagnostic offering that uses urine sampling, NGS-based microRNA profiling, and machine learning models to estimate risk for multiple cancer types. Available both as a home (remote) collection kit and via partner medical institutions.
Services
Design and execution of joint clinical research projects with university hospitals and medical centers for assay evaluation and validation.
R&D services to develop urine-based molecular assays (microRNA, cfDNA, EV) and to identify disease-associated biomarker signatures.
Provision and operation of a web-based portal for ordering tests, tracking sample progress, delivering electronic reports, and handling payments.
Design and execution of joint clinical research projects with university hospitals and medical centers for assay evaluation and validation.
R&D services to develop urine-based molecular assays (microRNA, cfDNA, EV) and to identify disease-associated biomarker signatures.
Provision and operation of a web-based portal for ordering tests, tracking sample progress, delivering electronic reports, and handling payments.
Expertise Areas
- Urine-based liquid biopsy and non-invasive diagnostics
- Biomarker discovery for cancer (microRNA, cfDNA, extracellular vesicles)
- Nanomaterials for biomolecule capture
- NGS-based molecular profiling
Key Technologies
- Urine microRNA sequencing (NGS)
- Nanowire-based extracellular vesicle capture
- cfDNA capture-and-release chemistry
- Proteomics for EV membrane proteins (mass spectrometry)
News & Updates
On May 31, 2023, COO Miga Mizunuma will deliver a lecture on the use of microRNA in urine for liquid biopsy at an online seminar hosted by Dialogue Co., Ltd., as part of a series on key technologies for next-generation drug discovery.
Craif's CEO and CTO featured in media articles about cancer detection technology and company activities
Various media outlets have featured Craif's activities, including articles on cancer screening tests, company seminars, and interviews with leadership about early detection and innovative healthcare solutions.
The JST Research and Development Strategy Center's report highlighted Craif as a key player among Japanese biotech startups, emphasizing its innovative approach to early disease detection.
On May 31, 2023, COO Miga Mizunuma will deliver a lecture on the use of microRNA in urine for liquid biopsy at an online seminar hosted by Dialogue Co., Ltd., as part of a series on key technologies for next-generation drug discovery.
Craif's CEO and CTO featured in media articles about cancer detection technology and company activities
Various media outlets have featured Craif's activities, including articles on cancer screening tests, company seminars, and interviews with leadership about early detection and innovative healthcare solutions.
The JST Research and Development Strategy Center's report highlighted Craif as a key player among Japanese biotech startups, emphasizing its innovative approach to early disease detection.